title: How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society.
authors.forename: David J
authors.initials: DJ
authors.lastname: Gladstone
authors.forename: William H
authors.initials: WH
authors.lastname: Geerts
authors.forename: James
authors.initials: J
authors.lastname: Douketis
authors.forename: Noah
authors.initials: N
authors.lastname: Ivers
authors.forename: Jeff S
authors.initials: JS
authors.lastname: Healey
authors.forename: Kori
authors.initials: K
authors.lastname: Leblanc
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D057189:Checklist; D003376:Counseling; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D055118:Medication Adherence; D018570:Risk Assessment; D020521:Stroke / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants